Literature DB >> 8886921

Locally-confined signet-ring cell carcinoma of the prostate: a case report of a long-term survivor.

K Yoshimura1, I Fukui, Y Ishikawa, H Maeda, T Yamauchi, T Kawai.   

Abstract

It is generally believed that signet-ring cell carcinoma (SRCC) of the prostate is a high-grade neoplasm with a poor prognosis. We report a case of a long-term survivor diagnosed with localized prostatic SRCC (T3N0M0), who has been alive without any clinical evidence of disease for 100 months after combination therapy which consisted of local irradiation and hormone administration. A posttreatment needle biopsy confirmed the pathological complete response.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8886921     DOI: 10.1111/j.1442-2042.1996.tb00566.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  4 in total

Review 1.  Primary signet ring cell carcinoma of the prostate.

Authors:  Jonathan N Warner; Leah Y Nakamura; Anna Pacelli; Mitchell R Humphreys; Erik P Castle
Journal:  Mayo Clin Proc       Date:  2010-12       Impact factor: 7.616

2.  Primary Signet Ring Cell Carcinoma of the Prostate: A Rare Case Report.

Authors:  Alper Gök; Can Tuygun; Müge Akmansu; Ayşegül Aksakal Uslu; Ibrahim Güven Kartal; Fatih Sandikçi; Osman Raif Karabacak; Azmi Levent Sağnak; Hikmet Topaloğlu; Hamit Ersoy
Journal:  J Clin Med       Date:  2018-08-15       Impact factor: 4.241

3.  Diagnosis and Management of Primary Prostatic Signet Ring Cell Carcinoma: Single-Center Experience.

Authors:  Pu Li; Zihan Zhou; Meiling Bao; Jie Li; Xiaoxin Meng; Bianjiang Liu; Min Tang
Journal:  Am J Mens Health       Date:  2022 Mar-Apr

4.  Immunohistochemical analysis of PD-L1 and tumor-infiltrating immune cells expression in the tumor microenvironment of primary signet ring cell carcinoma of the prostate.

Authors:  Qi-Liang Teng; Xin-Rui Yang; Shuang Wen; Zhi-Hong Dai; Hong-Long Wang; Tian-Qing Liu; Liang Wang; Bo Fan; Zhi-Yu Liu
Journal:  Asian J Androl       Date:  2022 Sep-Oct       Impact factor: 3.054

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.